- Home
- PSF vs KROS Comparison
PSF vs KROS Comparison
Compare PSF & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PSF | KROS |
|---|---|---|
| Founded | 2010 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 241.8M | 206.0M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | PSF | KROS |
|---|---|---|
| Price | $18.66 | $11.72 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $21.86 |
| AVG Volume (30 Days) | 42.8K | ★ 152.3K |
| Earning Date | 01-01-0001 | 05-06-2026 |
| Dividend Yield | ★ 7.69% | N/A |
| EPS Growth | N/A | ★ 146.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $243,864,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $2,751.79 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $18.48 | $9.69 |
| 52 Week High | $21.16 | $22.55 |
Technical Indicators
Market Signals| Indicator | PSF | KROS |
|---|---|---|
| Relative Strength Index (RSI) | 32.98 | 58.43 |
| Support Level | $18.48 | $10.59 |
| Resistance Level | $20.10 | $12.20 |
| Average True Range (ATR) | 0.16 | 0.40 |
| MACD | -0.01 | 0.04 |
| Stochastic Oscillator | 23.60 | 72.59 |
Price Performance
Historical ComparisonAbout PSF Cohen & Steers Select Preferred and Income Fund Inc.
Cohen & Steers Select Preferred and Income Fund Inc is a diversified, closed-end investment company. The Fund's primary investment objective is high current income with capital appreciation as its secondary objective. The Fund invests at least of its Managed Assets in preferred and other income securities issued by U.S. and non-U.S. companies.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.